COMPANY:

Syantra

"Syantra, Inc...announced that it has received funding from Alberta Innovates to support expanded clinical studies for investigating the Onco-ID: Breast blood test in women at elevated risk of breast cancer. The funding from Alberta Innovates AICE (Accelerating Innovations into CarE) Market Access program will both complement recent funding by the United States Department of Defense and support a pilot study with Jessica Treviño Jones, MD, of the Mays Cancer Center at The University of Texas Health Science Center at San Antonio (UT Health San Antonio)....The AICE funding will support critical work for FDA filings and Syantra's move into the US market. This includes expanding clinical validation data for women with dense breast tissue and other risk factors and generating pilot data on the use of the test."

"Syantra, Inc...announced it has filed an international patent application for its pioneering platform for the early detection of cancer and other diseases. The application also extends to methodology for the development of treatments and other methods of intervention."

"Cancer diagnostics developer Syantra said Wednesday that it has raised C$4.9 million (US$3.6 million) in a Series A-1 financing round...Syantra said it will use the Series A-1 funding to fast-track the clinical validation and commercialization of the breast cancer test."

"The University of Calgary is working with Cornell University to clinically validate a liquid biopsy test for the early detection of breast cancer with the support of approximately $2.4 million in funding from the US Department of Defense."

"Today, Syantra...announced additions to their Intellectual property (IP) portfolio as well as a strategic partnership with Limmi, a US-based technology company using AI-driven insights to power next generation disease detection and management techniques. These achievements mark significant milestones for Syantra and represent major advancements in understanding human disease....The newly announced partnership with Limmi provides a scalable AI-powered platform to drive novel insights from clinical data and to ultimately enhance Syantra's ability to detect various cancers at early stages."

"Syantra announced...that it has obtained CE marking for the Syantra DX™ Breast Cancer test. Syantra DX™ Breast Cancer is a minimally invasive blood test for the detection of an active breast cancer signature - in the earliest stages when it is easier to treat."